Premium
The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP‐receptor
Author(s) -
Lawler Orlaith A,
Miggin Sinead M,
Kinsella B Therese
Publication year - 2001
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0704033
Subject(s) - cerivastatin , receptor , statin , pharmacology , lovastatin , hek 293 cells , chemistry , prostanoid , endocrinology , biology , biochemistry , cholesterol , pravastatin
The prostanoid‐IP receptor may be unique among G protein coupled receptors in that it is isoprenylated. In this study, we investigated the effects of the statins lovastatin and cerivastatin on signalling by the mouse (m) IP and the human (h) IP receptors, over‐expressed in human embryonic kidney (HEK) 293 cells and by the hIP receptor, endogenously expressed in human erythroleukaemia cells. Both statins significantly reduced IP receptor‐mediated cyclic AMP generation and intracellular calcium ([Ca 2+ ] i ) mobilization in a time and concentration dependent manner but had no effect on signalling by the non‐isoprenylated β 2 adrenergic receptor or by the human prostanoid‐TP receptor isoforms. Cerivastatin (IC 50 , 50 – 90 n M ) was significantly more potent than lovastatin (IC 50 , 0.80 – 4.2 μ M ) in inhibiting IP receptor signalling. Whereas IC 50 values indicated that the hIP receptor was significantly more sensitive than the mIP receptor to the statins, the extent of inhibition of cyclic AMP generation by the mIP receptor was significantly greater than that of the hIP receptor to either statin, even at the highest concentrations used. Pretreatment with either statin significantly reduced IP receptor mediated desensitization of signalling by the h.TPα, but not by the h.TPβ, receptor isoform. These data generated in whole cells point to the possibility that statin therapy may interfere with IP receptor signalling in vivo ; such interference may be extenuated under conditions where circulating statin levels are elevated and may account, in part, for some of the pleiotropic affects of the statins not attributed solely to their lipid lowering properties.British Journal of Pharmacology (2001) 132 , 1639–1649; doi: 10.1038/sj.bjp.0704033